Life Science REIT PLC Result of AGM
23 Maio 2024 - 1:00PM
RNS Regulatory News
RNS Number : 7294P
Life Science REIT PLC
23 May 2024
Life Science REIT
plc
(the
"Company")
LEI: 213800RG7JNX7K8F7525
23 May
2024
Annual General Meeting
("AGM") Results
The Company announces that at its
Annual General Meeting held earlier today all the resolutions set
out in the Notice of Annual General Meeting were passed. All
resolutions were voted on by way of a
poll. The results of the poll for
each resolution were as follows:
|
Resolution
|
For
|
Against
|
Votes
Withheld
(No. of
shares)
|
|
No. of
shares
|
%
|
No. of
shares
|
%
|
|
1. To receive and
approve the annual report and financial statements
|
247,928,546
|
99.99%
|
14,663
|
0.01%
|
26,709
|
|
2. To receive and
approve the Directors' remuneration report
|
247,684,045
|
99.97%
|
68,743
|
0.03%
|
217,130
|
|
3. To approve the
Company's dividend payment policy
|
247,966,918
|
99.99%
|
3,000
|
0.01%
|
0
|
|
4. To re-elect Claire
Boyle as a Director of the Company
|
229,246,645
|
95.31%
|
11,291,786
|
4.69%
|
7,431,487
|
|
5. To re-elect Sally Ann
Forsyth as a Director of the Company
|
217,454,934
|
94.13%
|
13,561,582
|
5.87%
|
16,953,402
|
|
6. To re-elect Michael
Taylor as a Director of the Company
|
238,575,348
|
99.18%
|
1,963,083
|
0.82%
|
7,431,487
|
|
7. To re-elect Richard
Howell as a Director of the Company
|
238,572,783
|
99.18%
|
1,965,648
|
0.82%
|
7,431,487
|
|
8. To re-appoint
Deloitte LLP as Auditor to the Company
|
247,897,047
|
99.97%
|
64,398
|
0.03%
|
8,473
|
|
9. To authorise the
Audit and Risk Committee to determine the remuneration of the
Auditor to the Company
|
247,916,572
|
99.98%
|
53,346
|
0.02%
|
0
|
|
10. To authorise the Directors
to allot equity securities
|
222,777,035
|
89.84%
|
25,192,883
|
10.16%
|
0
|
|
11. To authorise the Directors
to disapply pre-emption rights*
|
232,274,638
|
93.68%
|
15,668,571
|
6.32%
|
26,709
|
|
12. To authorise the Directors
to disapply pre-emption rights for the purposes of financing an
acquisition or other capital investment*
|
231,970,086
|
93.58%
|
15,920,407
|
6.42%
|
79,425
|
|
13. To approve the purchase of
the Company's own shares*
|
236,334,255
|
95.31%
|
11,635,663
|
4.69%
|
0
|
|
14. That a general meeting,
other than an AGM, may be called on not less than 14 clear days'
notice*
|
244,386,609
|
98.56%
|
3,580,744
|
1.44%
|
2,565
|
*special resolution
|
NOTES:
|
|
|
1.
|
All resolutions were
passed.
|
|
2.
|
Percentages have been rounded to two
decimal places.
|
|
3.
|
Proxy appointments which gave
discretion to the Chair of the AGM have been included in the "For"
total for the appropriate resolution.
|
|
4.
|
Votes "For" and "Against" any
resolution are expressed as a percentage of votes validly cast for
that resolution.
|
|
5.
|
A "Vote withheld" is not a vote in
law and is not counted in the calculation of the percentage of
shares voted "For" or "Against" any resolution.
|
|
6.
|
The number of shares in issue at
6:00 pm. on 21 May 2024 was 350,000,000 ordinary shares, carrying
one vote each, and at that time, the Company did not hold any
shares in treasury.
|
|
7.
|
The full text of the resolutions
passed at the AGM can be found in the Notice of Annual General
Meeting which is available on the Company's website at
https://lifesciencereit.co.uk/investors/shareholder-information/
|
Enquiries:
|
Link Company Matters Limited - Company
Secretary
|
|
|
labs_cosec@linkgroup.co.uk
|
|
|
|
|
|
Ironstone Asset Management - Investment
Adviser
|
|
|
Simon Farnsworth/ Joanna
Waddingham
|
via Buchanan below
|
|
|
|
|
Panmure Gordon - Joint Corporate Broker
|
+44 20 7886 2500
|
|
Alex Collins / Tom
Scrivens
|
|
|
|
|
|
Jefferies International Limited - Joint Corporate
Broker
|
+44 20 7029 8000
|
|
Tom Yeadon
|
|
|
G10
Capital Limited - AIFM
|
+44 20 7397 5450
|
|
Verity Morgan-Jones / Maria
Baldwin
|
|
|
Buchanan - Financial PR
|
+44 20 7466 5000
|
|
Mark Court / Henry Wilson / Verity
Parker
|
|
|
LifeSciencereit@buchanan.uk.com
|
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGAJMATMTATBPI
Life Science Reit (LSE:LABS)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Life Science Reit (LSE:LABS)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
